Rosa Ruiz-Valderas

606 total citations
26 papers, 457 citations indexed

About

Rosa Ruiz-Valderas is a scholar working on Infectious Diseases, Virology and Hepatology. According to data from OpenAlex, Rosa Ruiz-Valderas has authored 26 papers receiving a total of 457 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Infectious Diseases, 15 papers in Virology and 11 papers in Hepatology. Recurrent topics in Rosa Ruiz-Valderas's work include HIV/AIDS drug development and treatment (18 papers), HIV Research and Treatment (15 papers) and Hepatitis C virus research (11 papers). Rosa Ruiz-Valderas is often cited by papers focused on HIV/AIDS drug development and treatment (18 papers), HIV Research and Treatment (15 papers) and Hepatitis C virus research (11 papers). Rosa Ruiz-Valderas collaborates with scholars based in Spain and United States. Rosa Ruiz-Valderas's co-authors include Luís F. López‐Cortés, Pompeyo Viciana, Jerónimo Pachón, Eva María León Jiménez, Alicia Gutiérrez‐Valencia, Almudena Torres-Cornejo, Omar J. BenMarzouk‐Hidalgo, Elisa Cordero, Ana Marín‐Niebla and Carmen Claro and has published in prestigious journals such as PLoS ONE, Clinical Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Rosa Ruiz-Valderas

25 papers receiving 442 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rosa Ruiz-Valderas Spain	12	342	189	160	52	46	26	457
James P. Lavelle United States	11	438 1.3×	473 2.5×	189 1.2×	20 0.4×	43 0.9×	14	732
Minh Lê France	14	402 1.2×	217 1.1×	186 1.2×	70 1.3×	140 3.0×	53	644
Annie Fang United States	13	155 0.5×	117 0.6×	45 0.3×	30 0.6×	14 0.3×	29	394
Daryl S. Schiller United States	10	190 0.6×	130 0.7×	200 1.3×	13 0.3×	7 0.2×	16	470
Roberto Ortiz United States	8	967 2.8×	275 1.5×	624 3.9×	20 0.4×	64 1.4×	17	1.0k
Amelia S. Petry United States	7	367 1.1×	119 0.6×	209 1.3×	78 1.5×	64 1.4×	9	423
Louis Sloan United States	11	545 1.6×	111 0.6×	431 2.7×	26 0.5×	26 0.6×	18	717
Andrew Luber United States	9	315 0.9×	120 0.6×	167 1.0×	40 0.8×	28 0.6×	22	395
Patricia K. Mydlow United States	6	205 0.6×	131 0.7×	87 0.5×	72 1.4×	51 1.1×	7	367
Michael Zilly Germany	12	281 0.8×	97 0.5×	169 1.1×	61 1.2×	24 0.5×	17	376

Countries citing papers authored by Rosa Ruiz-Valderas

Since Specialization

Citations

This map shows the geographic impact of Rosa Ruiz-Valderas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rosa Ruiz-Valderas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rosa Ruiz-Valderas more than expected).

Fields of papers citing papers by Rosa Ruiz-Valderas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rosa Ruiz-Valderas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rosa Ruiz-Valderas. The network helps show where Rosa Ruiz-Valderas may publish in the future.

Co-authorship network of co-authors of Rosa Ruiz-Valderas

This figure shows the co-authorship network connecting the top 25 collaborators of Rosa Ruiz-Valderas. A scholar is included among the top collaborators of Rosa Ruiz-Valderas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rosa Ruiz-Valderas. Rosa Ruiz-Valderas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

BenMarzouk‐Hidalgo, Omar J., Almudena Torres-Cornejo, Alicia Gutiérrez‐Valencia, et al.. (2015). Higher Activation in CD4 ⁺ T Cells But Similar Viral Control Among HIV/Hepatitis C Virus-Coinfected Patients on a Simplification Monotherapy. AIDS Research and Human Retroviruses. 32(1). 6–11. 4 indexed citations

Gutiérrez‐Valencia, Alicia, Rosa Ruiz-Valderas, Omar J. BenMarzouk‐Hidalgo, et al.. (2015). Telaprevir and Ribavirin Interaction: Higher Ribavirin Levels Are Not Only Due to Renal Dysfunction during Triple Therapy. Antimicrobial Agents and Chemotherapy. 59(6). 3257–3262. 2 indexed citations

BenMarzouk‐Hidalgo, Omar J., Almudena Torres-Cornejo, Alicia Gutiérrez‐Valencia, et al.. (2015). Differential Effects of Viremia and Microbial Translocation on Immune Activation in HIV-Infected Patients Throughout Ritonavir-Boosted Darunavir Monotherapy. Medicine. 94(17). e781–e781. 14 indexed citations

Gutiérrez‐Valencia, Alicia, Rosa Ruiz-Valderas, Omar J. BenMarzouk‐Hidalgo, et al.. (2015). Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?. Medicine. 94(43). e1743–e1743. 1 indexed citations

Rivero‐Juárez, Antonio, Luís F. López‐Cortés, Ángela Camacho, et al.. (2014). HCV Viral Decline at Week 2 of Peg-IFN-Alpha-2a/RBV Therapy as a Predictive Tool for Tailoring Treatment in HIV/HCV Genotype 1 Co-Infected Patients. PLoS ONE. 9(6). e99468–e99468. 2 indexed citations

BenMarzouk‐Hidalgo, Omar J., Almudena Torres-Cornejo, Alicia Gutiérrez‐Valencia, et al.. (2013). Immune activation throughout a boosted darunavir monotherapy simplification strategy. Clinical Microbiology and Infection. 20(12). 1297–1303. 9 indexed citations

Rivero‐Juárez, Antonio, Luís F. López‐Cortés, Ángela Camacho, et al.. (2013). The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype. AIDS. 27(12). 1941–1947. 5 indexed citations

Torres-Cornejo, Almudena, Omar J. BenMarzouk‐Hidalgo, Alicia Gutiérrez‐Valencia, et al.. (2013). Cellular HIV reservoir replenishment is not affected by blip or intermittent viremia episodes during darunavir/ritonavir monotherapy. AIDS. 28(2). 201–208. 14 indexed citations

Gutiérrez‐Valencia, Alicia, Rosa Ruiz-Valderas, Almudena Torres-Cornejo, et al.. (2013). Role of Ritonavir in the Drug Interactions Between Telaprevir and Ritonavir-Boosted Atazanavir. Clinical Infectious Diseases. 58(2). 268–273. 9 indexed citations

10.

López‐Cortés, Luís F., Rosa Ruiz-Valderas, María Francisca González‐Escribano, et al.. (2012). Influence of IL28B Polymorphisms on Response to a Lower-Than-Standard Dose peg-IFN-α 2a for Genotype 3 Chronic Hepatitis C in HIV-Coinfected Patients. PLoS ONE. 7(1). e28115–e28115. 5 indexed citations

11.

Rivero‐Juárez, Antonio, Luís F. López‐Cortés, Ángela Camacho, et al.. (2012). Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients. PLoS ONE. 7(11). e48959–e48959. 1 indexed citations

12.

Gutiérrez‐Valencia, Alicia, et al.. (2011). Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily versus 200 mg of etravirine twice daily in HIV-infected patients. Journal of Antimicrobial Chemotherapy. 67(3). 681–684. 10 indexed citations

13.

Domínguez-Herrera, Juan, Fernando Docobo-Pérez, Rafael López-Rojas, et al.. (2011). Efficacy of Daptomycin versus Vancomycin in an Experimental Model of Foreign-Body and Systemic Infection Caused by Biofilm Producers and Methicillin-Resistant Staphylococcus epidermidis. Antimicrobial Agents and Chemotherapy. 56(2). 613–617. 33 indexed citations

14.

López‐Cortés, Luís F., Pompeyo Viciana, Rosa Ruiz-Valderas, et al.. (2010). Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study. AIDS Research and Therapy. 7(1). 5–5. 4 indexed citations

15.

Gutiérrez‐Valencia, Alicia, Rosa Ruiz-Valderas, Luís Jiménez, et al.. (2008). Role of Pegylated Interferon-α-2a and Ribavirin Concentrations in Sustained Viral Response in HCV/HIV-Coinfected Patients. Clinical Pharmacology & Therapeutics. 84(5). 573–580. 15 indexed citations

16.

López‐Cortés, Luís F., Rosa Ruiz-Valderas, Antonio Rivero, et al.. (2007). Efficacy of Low-Dose Boosted Saquinavir Once Daily Plus Nucleoside Reverse Transcriptase Inhibitors in Pregnant HIV-1-Infected Women With a Therapeutic Drug Monitoring Strategy. Therapeutic Drug Monitoring. 29(2). 171–176. 17 indexed citations

17.

López‐Cortés, Luís F., Rosa Ruiz-Valderas, Josefa Ruiz‐Morales, et al.. (2006). Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen. Journal of Antimicrobial Chemotherapy. 58(5). 1017–1023. 19 indexed citations

18.

López‐Cortés, Luís F., et al.. (2005). Therapeutic drug monitoring of efavirenz: trough levels cannot be estimated on the basis of earlier plasma determinations.. PubMed. 39(5). 551–6. 22 indexed citations

19.

López‐Cortés, Luís F., et al.. (2002). Pharmacokinetic Interactions Between Efavirenz and Rifampicin in HIV-Infected Patients with Tuberculosis. Clinical Pharmacokinetics. 41(9). 681–690. 173 indexed citations

20.

López‐Cortés, Luís F., et al.. (2001). Intravitreal pharmacokinetics and retinal concentrations of ganciclovir and foscarnet after intravitreal administration in rabbits.. PubMed. 42(5). 1024–8. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact